CD40 and neoplasm: Another approach is to limit the recruitment of circulating monocytes at tumor sites by interfering with their response to chemoattractants [13, 52], or to re-activate macrophage cytotoxic potential with agonist anti-CD40 antibodies, TLR agonists or low dose irradiation [53, 54].